Clinical Development Outcomes: Dyne's success heavily depends on the favorable outcomes of its ongoing and future clinical trials for its therapeutic candidates, such as DYNE-251 for DMD and DYNE-101 for DM1; any failures in efficacy, safety, or study design could significantly harm the company's prospects.

Regulatory Approval Challenges: Even if clinical trials demonstrate positive results, Dyne must obtain regulatory approvals from agencies like the FDA and EMA for its product candidates, which is a lengthy, complex, and uncertain process that may not result in market authorization.

Intense Competition: The pharmaceutical and biotechnology industries are highly competitive, and Dyne faces competition from companies developing or marketing treatments for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), including those with more advanced products or greater resources.